

# In Vivo Paracrine Interaction between Urokinase and Its Receptor: Effect on Tumor Cell Invasion

Liliana Ossowski,\* Garfield Clunie,\* Maria-Teresa Masucci,† and Francesco Blasi‡

\*The Mount Sinai School of Medicine, Division of Medical Oncology, New York 10029; and †University of Copenhagen, Institute of Microbiology, Copenhagen, Denmark

**Abstract.** Numerous studies have linked the production of increased levels of urokinase type plasminogen activator (uPA) with the malignant phenotype. It has also been shown that a specific cell surface receptor can bind uPA through a domain distinct and distant from the proteolytic domain. In an in vivo model of invasion, consisting of experimentally modified chorioallantoic membrane (CAM) of a chick embryo, only cells that concurrently expressed both uPA and a receptor for uPA, and in which the receptor was saturated with uPA, were efficient in invasion. To test whether uPA produced by one cell can, in a paracrine fashion, affect the invasive capacity of a receptor-expressing cell, we transfected LB6 mouse cells with human uPA (LB6[uPA]), or human uPA-receptor cDNA (LB6[uPAR]). LB6(uPA) cells released into the medium 1–2 Ploug units of human uPA per 10<sup>6</sup> cells

in 24 h. The LB6(uPAR) cells expressed on their surface ~12,000 high affinity (K<sub>d</sub> 1.7 × 10<sup>-10</sup> M) uPA binding sites per cell. Unlabeled LB6(uPA) and <sup>125</sup>I-UdR-labeled LB6(uPAR) cells were coinoculated onto experimentally wounded and resealed CAMs and their invasion was compared to that of homologous mixtures of labeled and unlabeled LB6(uPAR) or LB6(uPA) cells. Concurrent presence of both cell types in the CAMs resulted in a 1.8-fold increase of invasion of the uPA-receptor expressing cells. A four-fold stimulation of invasion was observed when cells were cocultured in vitro, prior to in vivo inoculation. Enhancement of invasion was prevented in both sets of experiments by treatment with specific antihuman uPA antibodies, indicating that uPA was the main mediator of the invasion-enhancing, paracrine effect on the receptor-expressing cells.

**N**UMEROUS studies have shown that proteolytic enzymes produced by tumor cells participate in the degradation of components of the extracellular matrix and basement membrane, thus, facilitating the invasion of surrounding tissues (Dano et al., 1985; Jones and DeClerc, 1980; Mignatti et al., 1986; Mullins and Rohlich, 1983; Liotta and Stettler-Stevens, 1989; Sas et al., 1986; Sloan et al., 1990; Yagel et al., 1989). Existing evidence suggests that these enzymes are activated and, most likely, utilized sequentially (He et al., 1989; Mignatti et al., 1986; Paranjpe et al., 1980; Werb et al., 1977).

Urokinase type plasminogen activator, a serine protease, has been linked with the malignant phenotype in experimental and naturally occurring tumors (Axelrod et al., 1989; Duffy and O'Grady 1984; Janicke et al., 1990; Markus, 1988; Mira y Lopez and Ossowski, 1987; Ossowski and Reich, 1983; Ossowski, 1988b; Saksela and Rifkin, 1988; Testa and Quigley, 1990; Unkeless et al., 1973; Yu and Schultz, 1990). It is produced and secreted by most cells in the form of a proenzyme (Nielsen et al., 1982; Wun et al., 1982) which is activated by a single proteolytic cleavage. In

some tumors, urokinase type plasminogen activator (uPA)<sup>1</sup> is constitutively produced at very high levels, while in others the enzyme level can be substantially increased by growth factors and hormones (Dano et al., 1985). The natural substrate of uPA, plasminogen, is a zymogen present in high concentration in plasma and other body fluids. uPA converts plasminogen into an active serine protease, plasmin (Reich, 1978), which is known to degrade directly several glycoprotein components of the basement membrane and extracellular matrix and to contribute indirectly to the degradation of collagen (He et al., 1989; Mignatti et al., 1986; Paranjpe et al., 1980; Werb et al., 1977).

Although the localization of proteolytic enzymes on the cell surface was suspected for many years (Chapman et al., 1982; Quigley, 1976), uPA was the first enzyme for which a cell surface receptor had been identified (Stoppelli et al., 1985; Vassalli et al., 1985) and cloned (Roldan et al., 1990). We have shown that receptor-bound uPA retains its proteolytic activity and that, under most conditions, the binding of the enzyme does not induce rapid down-regulation of the receptor-uPA complex (Cubellis et al., 1986; Ossowski,

Maria-Teresa Masucci's current address is Institute of General Pathology, University of Naples 1st Medical School, Naples, Italy.

1. *Abbreviations used in this paper:* CAM, chorioallantoic membrane; uPA, urokinase type plasminogen activator.

1988a). These properties permit the cell to concentrate a proteolytic activity on its surface. Since invasion requires that extracellular matrix be degraded in the immediate vicinity of an advancing cell, we argued that cells equipped with the uPA receptor, should be more effective in invasion, provided they produced sufficient levels of uPA. This hypothesis was tested in an *in vivo* model of invasion consisting of a modified chick embryo chorioallantoic membrane (Ossowski, 1988a). Our results showed that the mere production of high levels of uPA, in the absence of surface receptors, was inadequate in endowing a tumor cell with maximal invasive potential.

There is a growing recognition of the intimate reciprocal interactions that may exist between tumor and normal stromal cells and the role they may play in changing the propensity of tumors to grow and invade (Basset et al., 1990; Camps et al., 1990; Chiquet Ehrisman et al., 1989; Rand Pritchett et al., 1989). Evidence supporting the idea that interactions between tumor cells may lead to the emergence of malignantly dominant subpopulations has also been accumulating (Kerbel, 1990). Moreover, it has been shown recently that in colon carcinomas the uPA receptor is produced by tumor cells, while uPA is produced by the surrounding fibroblasts (Pyke et al., 1991). The availability of a molecular clone of uPA and the recent cloning of the uPA receptor afforded the first opportunity to analyze genetically whether uPA and its receptor interact in a paracrine fashion and to determine the functional consequences of such interaction.

Mouse LB6 cells were stably transfected with either human uPA cDNA or human uPA receptor cDNA. LB6 (uPA) cells produced high levels of uPA but, due to restrictions imposed by the species difference (human versus mouse) (Appella et al., 1987; Estreicher et al., 1989), the secreted human uPA did not bind to the endogenous receptor of LB6 cells. LB6 (uPAR) cells expressed human uPA receptor but did not produce detectable uPA activity, thus, the receptors on these cells remained unoccupied. We carried out a functional complementation analysis between these two cell types using a quantitative *in vivo* model of connective tissue invasion. We tested whether binding of uPA to its receptor enhanced the invasive ability of the receptor-transfected cells and whether a paracrine interaction between these two components is operative *in vivo*.

## Materials and Methods

### Materials

COFAL-negative embryonated eggs were obtained from Spafas, Inc. (Norwich, CT); DME and Geneticin from Gibco Laboratories (Grand Island, NY); FBS from Hazleton Research Products Inc. (Lenexa, KS); BSA from Armour Pharmaceutical Co. (Kankakee, IL);  $^{125}$ -IUdR (specific activity 2,200 Ci/mmol) from New England Nuclear (Boston, MA); Enzymobeads from BioRad Laboratories, Inc. (Richmond, CA); Trypsin from ICN Biomedicals, Inc. (Costa Mesa, CA); Carnation powdered milk (casein) from Carnation Company, (Los Angeles, CA); Dowex -1, chloride form, Triton X-100, and human urokinase standards from Sigma Chemical Co. (St. Louis, MO); and chromogenic substrate for plasmin (Spectrozyme PL) from American Diagnostica Inc. (Greenwich, CT). Recombinant, single chain human uPA was a generous gift from Abbott Laboratories (North Chicago, IL). Human plasminogen was purified from fresh frozen plasma as previously described (Deutsch and Mertz, 1970); anti-human uPA IgG (polyclonal and monoclonal) were as previously described (Ossowski et al., 1991). Mouse uPA was obtained from cultures of MSV-transformed 3T3 cells.

### Cell Lines

Mouse LB6 cells transfected with human uPA receptor cDNA under the control of the SV40 promoter have been described and designated clone 19 (Roldan et al., 1990). LB6 cells expressing human uPA cDNA (LB6 clone F) were prepared according to a previously described procedure (Nolli et al., 1989). Both cell types were cotransfected with the pSV-neo plasmid DNA. The cells were treated with 200  $\mu$ g/ml of Geneticin for 5 d every 4 to 5 wk. For clarity, throughout the manuscript we used the designation of LB6 (uPA) for the uPA-transfected cells and LB6 (uPAR) for uPA-receptor-transfected cells.

### Methods

**Quantitation of Tumor Cell Invasion of Chorioallantoic Membrane Mesenchyme.** The methods used were essentially as described previously (Ossowski, 1988a). Briefly, LB6 (uPA) or LB6 (uPAR) cells were labeled in culture for 20 h with 0.2  $\mu$ Ci/ml of  $^{125}$ -IUdR to a specific activity of 0.05 to 1.0 cpm/cell. Cells were washed extensively with DME with 5% FBS to remove free label, resuspended at  $3-4 \times 10^5$  cells per 50  $\mu$ l of PBS and inoculated on chorioallantoic membranes (CAMs) of embryos in which artificial air sacs were created 18 to 24 h before inoculation (wounded and resealed CAMs, see Ossowski, 1988a). Invasion was quantitated after 24 h of incubation. CAMs were washed with PBS, excised, and both the washes and the CAMs were counted in the gamma counter. The sum of these determinations provided the total number of recovered radioactive cells used for calculation of invasion. The CAMs were then treated with 0.05% trypsin in 1 mM EDTA and again counted in a gamma counter. This method allowed us to distinguish cells attached to the surface of CAMs, from those which invaded the CAMs and were thus protected from the proteolytic action of trypsin (Ossowski, 1988a). Invasion was expressed as percent of total recovered cells.

**Plasminogen Activator Determination.** We used the chromogenic substrate for plasmin (Spectrozyme PL) to assay PA activity (Mira y Lopez and Ossowski, 1987; Verheijen et al., 1982). Briefly, 10  $\mu$ l of sample to be tested was mixed with 105  $\mu$ l of Tris buffer (0.1 M, pH 8.1, with 0.1% Triton X-100) and 10  $\mu$ l of 0.2 mg/ml of purified human plasminogen in a 96-well, flat bottom tray. The mixtures were incubated for 2 h at 37°C, 15  $\mu$ l of 1 mg/ml of the chromogenic substrate was added and the generation of color was monitored in a multiplate reader (Dynatech Laboratories, Inc., Chantilly, VA) at 495 nm. A standard curve of human uPA (0.5–10 mU) was included with every assay.

**Identification of the Origin of Plasminogen Activator.** Two methods were used to determine the origin of uPA produced by mouse cells transfected with the human uPA cDNA. Lysates and conditioned media of these cells (10  $\mu$ l) were subjected to electrophoresis on SDS-PAGE and simultaneous determinations of molecular weight and activity were performed using zymography, essentially as described (Granelli-Piperno and Reich, 1978), except the casein from powdered milk, and not fibrinogen, was used in the indicator gels. Bands of lysis produced by the tested cells were compared to those produced by known, standard preparations of uPA. Species origin of uPA was also examined by mixing cell lysates and conditioned media ( $\sim$ 1 U of uPA/ml) with 50  $\mu$ g/ml of purified monoclonal antihuman uPA antibodies, and measuring the residual uPA activity of these mixtures in a chromogenic substrate assay. While the activity produced by the LB6 (uPA) cells was completely inhibited in this assay, a fourfold greater concentration of this antibody did not inhibit a standard preparation of mouse uPA.

**Receptor Binding Assay.** Recombinant, single chain human uPA (5  $\mu$ g) was iodinated to specific activity of  $4 \times 10^7$  cpm/ $\mu$ g protein, using Enzymobeads and procedures recommended by the manufacturer. Unbound iodine was removed by passage through a 1-ml prewashed Dowex-1 column. Cells to be tested were plated in 24-well trays at  $1 \times 10^5$  per well, incubated overnight, washed with DME with 20 mM Hepes and 1 mg/ml of BSA and incubated with dilutions of the radioactive uPA for 45 min at 4°C with, and without, 50-fold excess of unlabeled uPA. After three washes with DME-Hepes-BSA the cells were extracted with 1 N NaOH and the extracts counted in the gamma counter. To determine receptor-bound activity, cells were washed with DME-Hepes-BSA and then with 0.5 ml of Glycine/HCl, pH 3.0, for 3 min (Cubellis et al., 1986). The washes were neutralized and tested for uPA.

**Paracrine Saturation of Receptors in Mixtures of LB6 (uPA) and LB6 (uPAR) Cells.** We plated LB6 (uPA) cells ( $1 \times 10^6$ ) at the bottom of a 60-mm Cooper dish and the LB6 (uPAR) cells ( $8 \times 10^5$ ) on the inner surface of the Cooper dish cover. (The cover of the Cooper dish is indented so that its distance from the bottom of the dish is only 1 mm.) The bottoms and tops were incubated separately for 20 h. All cultures were then washed with

**Table I. Expression of Human uPA and uPA-receptors in Mouse Cells Transfected with Human cDNAs**

Cell type	uPA mU/10 <sup>6</sup> cells				uPA-receptor	
	Secreted		Cell associated		Number/cell	K <sub>d</sub>
	Mean	(SD)	Mean	(SD)		
LB6 (uPA)	1,726	(± 476)	1,047	(± 326)	0	N.A.
LB6 (uPAR)	Below detection		Below detection		11,700 (± 3,200)	1.7 (± 0.6) × 10 <sup>-10</sup> M

Cells transfected with the human uPA-receptor cDNA (clone 19 –LB6[uPAR]) or with the human uPA cDNA (clone F –LB6[uPA]), were plated in medium with 10% FBS, grown to semiconfluency, washed once to remove serum, and incubated for 20 h in serum-free medium. Conditioned media and cell lysates were assayed for human and mouse uPA production. (100% of the secreted uPA and 99% of the cell associated activity was inhibited by IgG against human uPA—see Materials and Methods). The binding of uPA to its receptor was determined using radioactive ligand; the number of receptor sites and K<sub>d</sub> were calculated from Scatchard plots (see Materials and Methods). The values given are the mean of three experiments. N.A., not applicable. The detection limit of the chromogenic assay is 1 Ploug mU/ml.

DME and the LB6 (uPA) (bottom of dishes) and LB6 (uPAR) cells (covers) were combined and incubated in 4 ml of DME. At 3, 7, and 20 h of coculture uPA activity was measured in samples of media and in the acidic (Glycine/HCl, pH 3) washes of the receptor-expressing cells.

## Results

### Characterization of the Transfected Cell Lines


LB6 cells transfected with human uPA cDNA expressed large amounts of human uPA of which ~60% was found in the medium and the rest was cell associated (Table I). The cell-associated activity was judged to be intracellular since it could neither be eluted by low pH treatment (Cubellis et al., 1986), nor degraded by prolonged exposure to trypsin (results not shown). The released and cell-associated uPAs were identified as being of human origin since their activity was completely blocked by specific monoclonal anti-human uPA IgG (results not shown). Moreover, zymographic analysis (Granelli-Piperno and Reich, 1978) showed that zones of lysis produced by the LB6 (uPA) cells corresponded to those produced by high molecular weight standard human uPA (Fig. 1). The rate of migration of cell-associated uPA was

slightly, but consistently, faster than that of the standard. At present, we do not have an explanation for this observation.

The analysis of uPA binding to the receptor-transfected cells revealed the presence of ~12,000 high affinity (K<sub>d</sub> of 1.7 (0.6) × 10<sup>-10</sup> M) specific human uPA binding sites per cell (Table I). The binding was found to be saturable and was completely competed by a 50 M excess of unlabeled human uPA (results not shown).

### Kinetics of Paracrine Saturation of uPA Receptors in Co-cultures

To determine the length of time required for paracrine loading of uPA receptors, LB6 (uPA) and LB6 (uPAR) cells were cocultivated in Cooper dishes for 3, 7, and 20 h. uPA activity was measured in aliquots of culture media (released activity) and in fractions obtained by brief incubation of each type of cells in low pH (receptor-bound activity—see Materials and Methods). The concentration of free uPA rose with essentially linear kinetics, reaching an estimated concentration of 7 × 10<sup>-11</sup> M at 20 h. Receptor-bound uPA also rose in a time-dependent manner, reaching at 20 h 3.3 times the level observed at 3 h. Based on the level of released uPA and the



**Figure 1.** Analysis of plasminogen activator production by LB6(uPA) and LB6(uPAR) cells. 10 μl of conditioned media or cell lysates of the two cell types were electrophoresed and assayed by zymography (Granelli-Piperno and Reich, 1978). For preparation of conditioned medium and cell lysates see legend to Table I. (lanes 1 and 2) LB6(uPAR); (lanes 3 and 4) LB6(uPA); (STD) standards; (lanes 1 and 3) conditioned media; (lanes 2 and 4) cell lysates. (h) Human uPA (55 and 37 kD); (m) mouse uPA (48 kD).

**Table II. Kinetics of uPA-receptor Filling in Co-cultures of uPA and Receptor Expressing Cells**

Time of co-culture	Cell type	uPA activity per dish		
		Medium		Receptor-bound
h		mU	M × 10 <sup>-11</sup>	mU
3	LB6(uPA)	324	1.4	0
	LB6(uPAR)			90
7	LB6(uPA)	590	2.6	0
	LB6(uPAR)			180
20	LB6(uPA)	1,533	7.0	0
	LB6(uPAR)			301

The uPA-producing LB6 (uPA) and the uPA-receptor-expressing LB6 (uPAR) cells, were plated at 1 × 10<sup>6</sup> or 8 × 10<sup>5</sup> cells, respectively, per Cooper dish (see Materials and Methods) in medium with 10% FBS, incubated for 20 h and, following two washes with serum-free medium, combined so that the two cell types faced each other and were separated only by a 1 mm thick layer of serum-free medium (see Materials and Methods). At the indicated times, conditioned medium uPA, and receptor-bound, acid releasable uPA, were measured (see Materials and Methods). uPA assay duplicates differed by <5%. The experiment was repeated two times with similar results. Specific activity used to convert mU to molar concentration was 100,000 U/mg protein.

**Table III. Stimulation of Receptor-expressing Cells Invasion by uPA-producing Cells**


Cells on CAM		Invasion of CAMs Radioactivity (% of total recovered)			
Labeled	Unlabeled	Mean	(SD)	Median	Range
LB6(uPAR)	LB6(uPAR)	5.4	(±3.3)	4.4	(2.3–12.3)
LB6(uPA)	LB6(uPA)	5.6	(±3.7)	4.4	(1.9–13.9)
OB6(uPAR)	LB6(uPA)	10.0	(±3.8)	11.5	(4.6–13.6)

Receptor expressing cells LB6(uPAR) or human uPA producing cells (LB6-uPA) were labeled in culture with 0.2  $\mu$ Ci/ml of  $^{125}$ -IUdR for 24 h. Before inoculation,  $1.5 \times 10^5$  labeled cells were combined with  $3 \times 10^5$  unlabeled receptor or uPA expressing cells and inoculated on CAMs in 50  $\mu$ l of PBS. Invasion of CAMs was measured 24 h postinoculation (for details see Materials and Methods and Ossowski, 1988a). The data shown are a summary of two identical experiments; each group included 12 embryos. Analysis of variance (Systat Statistics) gave a *p* value of 0.063. The *p* value for uPA + uPAR vs. uPAR was 0.032, for uPA + uPAR vs. uPA was 0.046, and for uPA vs. uPAR was 0.698.

established  $K_d$  (Table I), ~33% of the receptors would be expected to be filled with uPA after 20 h of co-cultivation. The measured level of receptor-bound uPA (Table II) indicated that a somewhat greater actual receptor occupancy may have been achieved.

### Interaction between uPA and uPA Receptor-producing Cells In Vivo

To test whether the presence in the CAM of uPA secreting cells would affect the efficiency of invasion we used a quantitative in vivo model of tumor invasion (Ossowski, 1988a). In this model 9-d-old embryos with artificially wounded CAMs were incubated until the wounds were sealed (usually 24–30 h) by a layer of fibroblasts resulting in structures partially resistant to tumor cell invasion. The model was adapted to allow a measurable, but low level, invasion by the receptor-transfected cells by reducing the time between



**Figure 2.** Enhancement of invasion of LB6(uPAR) cells by LB6(uPA) cells; coculture before CAM inoculation. Receptor-expressing cells LB6(uPAR) or uPA-producing LB6(uPA) cells were labeled in culture with  $^{125}$ -IUdR, mixed with an equal number of unlabeled cells of either the homologous or the heterologous type, and incubated for an additional 20 h. All cells were detached, washed, and each cell mixture ( $4 \times 10^5$  cells) was inoculated onto 10 CAMs wounded 18 h earlier, and incubated at 37° for 24 h, at which time invasion was

quantitated (see Materials and Methods). The difference between groups was statistically significant, *p* = 0.006 by analysis of variance; mixed cells vs. uPAR, *p* = 0.004, mixed cells vs. uPA, 0.008 and uPAR vs. uPA cells, *p* = 0.9. R.uPA, mixture of labeled receptor cells and unlabeled uPA cells; R.R, mixture of labeled and unlabeled receptor cells; uPA.uPA, mixture of labeled and unlabeled uPA cells.

**Table IV. Inhibition of Receptor-bound uPA by Specific Antibodies**

Antibody treatment	Plasminogen in uPA assay	uPA (% control)
–	+	100.0
–	–	0.7
+	+	1.4
+	–	1.7

Mixtures ( $5 \times 10^4$  cells each) of receptor-expressing and uPA-producing cells were co-cultured overnight in 24-well trays in DME with 10% FBS, detached, washed extensively, and incubated in suspension ( $1 \times 10^6$  cells/ml) with 50  $\mu$ g/ml of anti-human-uPA IgG for 1 h at 37°C. The cells were washed three times and incubated for 30 min at 37°C with 100  $\mu$ g/ml of human plasminogen. The amount of plasmin generated was measured using a chromogenic substrate (see Materials and Methods). The positive control (without antibodies, with plasminogen) generated 1.6 OD<sub>495</sub> U/h.

wounding and inoculation. LB6 (uPAR) cells were labeled in culture with  $^{125}$ -IUdR, and coinoculated with unlabeled LB6 (uPA) cells on the sealed CAMs. Labeled uPAR or uPA cells, mixed with homologous, unlabeled cells were used as controls. Results in Table III indicate that the coinoculation of uPA-producing cells leads to an enhancement of invasion by the receptor-expressing cells. Qualitatively similar results, showing an enhancement of invasion from 1.5- to 2.1-fold, were observed in eight additional experiments (results not shown).

Since the level of receptor saturation is dependent on the ligand concentration, and since under conditions of continuous uPA production, ligand concentration rises with time (see Table II), we tested whether receptor cells cocultured with uPA-producing cells for 20 h before inoculation on the CAMs would invade more efficiently. In this experiment the receptor cells were labeled with  $^{125}$ -IUdR before coculture. Control mixtures included labeled and unlabeled receptor cells and labeled and unlabeled uPA-producing cells. This approach produced a fourfold (*p* = 0.006) enhancement of receptor-expressing cell invasion by the uPA-producing cells (Fig. 2).

To test whether the enhancement of invasion was mediated solely via a transfer of uPA from an enzyme producing cell to a receptor expressing cell (paracrine mechanism) we car-

**Table V. The Effect of Anti-uPA Antibodies on Invasion**

Experiment	Inhibition of invasion (%)		
	Mean	(SD)	<i>P</i>
1	69.8	(±26.0)	0.013
2	85.8	(±12.0)	0.008

LB6(uPAR) cells were labeled in culture with  $^{125}$ -IUdR for 20 h, detached, mixed with an equal number of LB6(uPA) cells, and further incubated in 60-mm dishes for 24 h. The following preimmune or anti-human uPA IgGs were used: in experiment 1, in which 18 embryos were used, 300  $\mu$ g of monoclonals and 1 mg of rabbit polyclonals added to cells immediately before inoculation and also added to CAMs 1 h before inoculation; in experiment 2, in which 16 embryos were used, mAbs (50  $\mu$ g/ml) were added to cells for the 20 h of in vitro coculture and also added to the inoculum. Invasion of cells treated with similar concentrations of normal IgG (mouse or rabbit) was considered 100% and used to calculate percent inhibition. The significance of the difference between the control and antibody treated groups (*p* values) was tested using the *t* test.

ried out the invasion assays in the presence of specific inhibitory antihuman uPA antibodies. This antibody was capable of inhibiting receptor-bound uPA activity (see Table IV), indicating that the epitope it recognized was not hindered by binding to the receptor. Inclusion of the inhibitory antibodies in both experimental designs (Table III and Fig. 2) resulted in a significant inhibition of invasion (Table V).

## Discussion

Using a functional complementation analysis we showed that uPA produced by one cell can, by a paracrine in vivo interaction, modulate the invasive potential of a uPA-receptor-expressing tumor cell. This result is of particular interest for two reasons. First, it confirmed our previous observations which implicated uPA receptor in the enhancement of uPA-dependent invasion of CAMs (Ossowski, 1988a). Second, to the best of our knowledge, it represents the few documented cases in which a known mediator affected the malignant potential of tumor cells in vivo via a paracrine interaction.

Although the mechanism of enhancement of invasion by receptor-bound uPA is not yet understood, it may function by focusing the proteolytic activity on the cell surface. This notion is supported by the findings that plasmin generation on the surface of cells is more effective than in solution (Plow et al., 1986). One possible explanation for this effect may be found in the observation (Quax et al., 1991) that receptor-bound pro-uPA (the form commonly released by most cells) may be more susceptible to activation by plasmin. Other mechanisms responsible for the enhanced proteolysis by the receptor-bound uPA are currently being investigated.

The analysis of paracrine interactions between tumor cells and their role in the enhancement of malignancy was made possible by the availability of the molecular clones of uPA and its receptor and an in vivo model of invasion, which could be adapted to accommodate cells with greatly differing invasive potentials (Ossowski, 1988a). We have previously shown that under the most stringent conditions of the CAM model only highly malignant cells yielded measurable invasion (Ossowski, 1988a). These cells were found to produce, in addition to uPA, at least one other proteolytic enzyme belonging to the metalloproteinase family (Ossowski, L., manuscript in preparation). However, it was possible, by reducing the stringency of resistance of the CAM to invasion, to assess quantitatively even cells with marginal invasive potential such as the LB6 (uPAR) cells.

We found that inoculated individually, the transfected cells, even under conditions of low stringency, produced very low level of CAM invasion (Table III). Coinoculation of the two cell types enhanced the invasion of the receptor-expressing cells 1.8-fold. The relatively small enhancement was not unexpected since, although the LB6 (uPAR) bind uPA with high affinity ( $K_d$   $1.7 \times 10^{-10}$  M; Table I), the number of their plasma membrane binding sites (11,700) is lower (Table I) than that reported for highly malignant tumor cells ranging from 40,000 to 100,000 (Ossowski, 1988a; Schlechte et al., 1989). Also, Schlechte et al. (1989) have shown that the ability to invade in an in vitro model was correlated with the number of surface uPA receptors. Moreover, it should be kept in mind that coinoculation of the two cell types on the CAM, in which relatively small number of cells in suspension ( $3-4 \times 10^5$ ) encounter relatively large areas

of tissue, may not accurately represent the topography that exists in a primary tumor. This may reduce the effective concentration of uPA in the vicinity of receptor-expressing cells and thus reduce the level of receptor saturation by the enzyme. In spite of this relative inefficiency of the system, the results clearly show that uPA produced by one cell can be utilized, in a paracrine fashion, to potentiate the invasive ability of another cell. The fact that in experiments in which the two cell types were cocultured before inoculation the potentiation of invasion was much greater (Fig. 2), gives additional support to the notion that during the brief period (24 h) in the CAM, cell interactions may be less than optimal and that in a naturally developing tumor the paracrine effects may be of much greater magnitude.

We used inhibitory anti-human uPA IgGs to positively identify uPA as the mediator of the observed enhancing effect on invasion. This treatment, which specifically interrupted the paracrine interaction, greatly reduced the potentiation by LB6 (uPA) cells (Table V), implicating uPA as the main mediator of the effect. The magnitude of the inhibition indicated that no other paracrine signals, important for invasion of connective tissue, were exchanged between the two cell types.

Overall, using a functional complementation analysis of genetically engineered cells, we proved that specific paracrine interactions, involving uPA and its receptor, lead to increased tumor invasion in vivo. The significance of this finding is underscored by the recent observation showing that, in colon carcinomas in man, uPA and its receptor are produced by distinct populations of cells (Pyke et al., 1991), suggesting that interactions of the kind described here may be operative and necessary for the expression of the full malignant potential of tumors.

The authors would like to thank Dr. R. Mira y Lopez for critical reading of the manuscript, L. Decker for expert technical assistance, and Abbott Laboratory for the generous gift of recombinant single chain human uPA.

This work was supported by United States Public Health Service Research Grant CA-40758 to L. Ossowski, the Samuel Waxman Cancer Research Foundation, and grants from the Danish Cancer Society (F. Blasi). M. T. Masucci was a fellow of the Italian Association for Cancer Research.

Received for publication 10 May 1991 and in revised form 9 July 1991.

## References

- Appella, E., E. A. Robinson, S. J. Ulrich, M. P. Stopelli, A. Corti, G. Cassani, and F. Blasi. 1987. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. *J. Biol. Chem.* 262:4437-4440.
- Axelrod, J. H., R. Reich, and R. Miskin. 1989. Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. *Mol. Cell. Biol.* 9:2133-2141.
- Basset, P., J. P. Bellocq, C. Wolf, I. Stol, P. Hutin, J. M. Limacher, O. L. Podhajcer, M. P. Chenard, M. C. Rio, and P. Chambon. 1990. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. *Nature (Lond.)* 348:699-704.
- Camps, J. L., S.-M. Chang, T. C. Hsu, M. R. Freeman, S.-J. Hong, H. E. Zhou, A. C. von Eschenbach, and L. W. K. Chung. 1990. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. *Proc. Natl. Acad. Sci. USA.* 87:75-79.
- Chapman, H. A., Z. Vavrin, and J. B. Hibbs. 1982. Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator. *Cell.* 28:653-662.
- Chiquet Ehrismann, R., P. Kella, and C. A. Pearson. 1989. Participation of tenascin and TGF-beta in reciprocal epithelial-mesenchymal interaction of MCF-7 cells and fibroblasts. *Cancer Res.* 49:4322-4325.
- Cubellis, M. V., M. L. Noll, G. Cassani, and F. Blasi. 1986. Binding of single chain urokinase to the urokinase receptor of human U937 cells. *J. Biol. Chem.* 261:15819-15822.

- Dano, K., P. A. Andreasen, J. Grondahl-Hansen, P. Kristensen, L. S. Nielsen, and L. Skriver. 1985. Plasminogen activators, tissue degradation, and cancer. *Adv. Cancer Res.* 44:139-266.
- Deutsch, D. G., and E. T. Mertz. 1970. Plasminogen purification from human plasma by affinity chromatography. *Science (Wash. DC)*. 170:1095-1096.
- Duffy, M. J., and P. O'Grady. 1984. Plasminogen activator and cancer. *Eur. J. Cancer Clin. Oncol.* 20:577-582.
- Estreicher, A., A. Wohlwend, D. Belin, W.-D. Schleuning, and J.-D. Vassalli. 1989. Characterization of the cellular binding site for the urokinase-type plasminogen activator. *J. Biol. Chem.* 264:1180-1189.
- Granelli-Piperno, A., and E. Reich. 1978. A study of protease-inhibitor complexes in biological fluids. *J. Exp. Med.* 148:223-234.
- He, C., S. M. Wilhelm, A. P. Pentland, B. L. Marmer, G. A. Grant, A. Z. Eisen, and G. I. Goldberg. 1989. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. *Proc. Natl. Acad. Sci. USA.* 86:2632-2636.
- Janicke, F., M. Schmitt, R. Hafter, A. Hollrieder, R. Babic, K. Ulm, W. Gossner, and H. Graeff. 1990. Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. *Fibrinolysis.* 4:69-78.
- Jones, P., and Y. A. DeClerck. 1980. Destruction of extracellular matrices containing glycoproteins, elastin and collagen by metastatic human tumor cells. *Cancer Res.* 40:3222-3227.
- Kerbel, R. 1990. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. *Adv. Cancer Res.* 55:87-130.
- Liotta, L., and W. Stetler-Stevenson. 1989. Metalloproteinases and malignant conversion: does correlation imply causality? *J. Natl. Cancer Inst.* 81:556-557.
- Markus, G. 1988. The relevance of plasminogen activators to neoplastic growth. A review of recent literature. *Enzyme.* 40:158-172.
- Mignatti, P., E. Robbins, and D. B. Rifkin. 1986. Tumor invasion through the human amniotic membrane; Requirement for a proteinase cascade. *Cell.* 47:487-498.
- Mira y Lopez, R., and L. Ossowski. 1987. Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumor responsiveness. *Cancer Res.* 47:3558-3564.
- Mullins, D. E., and S. T. Rohrich. 1983. The role of proteinases in cellular invasiveness. *Biochim Biophys. Acta.* 695:177-214.
- Nielsen, L. S., J. G. Hansen, L. Skriver, E. L. Wilson, K. Kalfolt, J. Zeuthen, and K. Dano. 1982. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. *Biochemistry.* 24:6410-6415.
- Nolli, M. L., E. Sarubbi, A. Corti, F. Robbiati, A. Soffientini, F. Blasi, F. Parenti, and G. Cassani. 1989. Production and characterization of human recombinant single chain urokinase-type plasminogen activator from mouse cells. *Fibrinolysis.* 3:101-106.
- Ossowski, L. 1988a. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell-surface bound urokinase. *J. Cell Biol.* 107:2437-2445.
- Ossowski, L. 1988b. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. *Cell.* 52:321-328.
- Ossowski, L., and E. Reich. 1983. Antibodies to plasminogen activator inhibit human tumor metastasis. *Cell.* 35:611-619.
- Ossowski, L., H. Russo-Payne, and E. L. Wilson. 1991. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. *Cancer Res.* 51:274-281.
- Paranjpe, M., L. Engel, N. Young, and L. Liotta. 1980. Activation of human breast carcinoma collagenase through plasminogen activator. *Life Sci.* 26:1223-1231.
- Plow, E. F., D. E. Freaney, J. Plescia, and L. A. Miles. 1986. The plasminogen activator system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. *J. Cell Biol.* 103:2411-2420.
- Pyke, C., P. Kristensen, E. Ralfkiaer, J. Grondahl-Hansen, J. Eriksen, and K. Dano. 1991. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. *Am. J. Pathol.* 138:1059-1067.
- Quax, P., N. Padersen, M.-T. Masucci, J. Weening-Verhoeff, K. Dano, J. Verheijen, and F. Blasi. 1991. Complement analysis of extracellular matrix degradation: enhancement of urokinase plasminogen activation by the urokinase receptor. *Cell Reg.* In press.
- Quigley, J. P. 1976. Association of a protease (plasminogen activator) with a specific membrane fraction isolated from transformed cells. *J. Cell Biol.* 71:472-476.
- Rand Pritchett, T., J. K. M. Wang, and P. A. Jones. 1989. Mesenchymal-epithelial interactions between normal and transformed tumor cells. *Cancer Res.* 49:2750-2754.
- Reich, R. Activation of plasminogen: a general mechanism for producing localized extracellular proteolysis. In *Molecular Basis for Biological Reproductive Processes*. R. D. Berlin, Herman. M., Lepow, I. H., and J. M. Tanzer editors. Academic Press, New York. 155-169.
- Roldan, A., M. V. Cubellis, M. T. Masucci, N. Behrendt, L. R. Lund, K. Dano, E. Appella, and F. Blasi. 1990. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell-surface plasmin-dependent proteolysis. *EMBO (Eur. Mol. Biol. Organ.) J.* 9:467-474.
- Saksela, O., and D. B. Rifkin. 1988. Cell-associated plasminogen activation: regulation and physiological functions. *Annu. Rev. Cell Biol.* 4:93-126.
- Sas, D. F., J. B. McCarthy, and L. T. Furcht. 1986. Clearing and release of basement proteins from substrates by metastatic tumor cell variants. *Cancer Res.* 46:3082-3089.
- Schlechte, W., G. Murano, and D. Boyd. 1989. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. *Cancer Res.* 49:6064-6069.
- Sloan, B. F., Robinson, D., and K. D. Honn. 1990. Role for cathepsin B and cystatins in tumor growth and progression. *Biol. Chem. Hoppe Seyler (Suppl).* 371:193-198.
- Stoppelli, M. P., A. Corti, A. Soffientini, G. Cassani, F. Blasi, and R. K. Assoian. 1985. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. *Proc. Natl. Acad. Sci. USA.* 82:4939-4943.
- Testa, J. E., and J. P. Quigley. 1990. The role of plasminogen activator in aggressive tumor behavior. *Cancer Metastasis Rev.* 9:353-367.
- Unkeless, J. C., A. Tobia, L. Ossowski, J. P. Quigley, D. B. Rifkin, and E. Reich. 1973. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. *J. Exp. Med.* 137:85-111.
- Vassalli, J.-D., D. Baccino, and D. Belin. 1985. A cellular binding site for the M<sub>r</sub> 55,000 form of the human plasminogen activator, urokinase. *J. Cell Biol.* 100:86-92.
- Verheijen, J. H., E. Mullaart, G. T. G. Chang, C. Kluft, and G. Wijngaards. 1982. A simple and sensitive spectrophotometric assay for intrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. *Thromb. Haemostasis.* 48:266-269.
- Werb, Z., C. L. Mainardi, C. A. Vater, and E. D. Harris. 1977. Endogenous activation of collagenase by rheumatoid synovial cells. *New Engl. J. Med.* 296:1017-1023.
- Wun, T.-C., L. Ossowski, and E. Reich. 1982. A proenzyme form of human urokinase. *J. Biol. Chem.* 257:7262-7268.
- Yagel, S., A. H. Warner, H. N. Nellans, P. K. Lala, C. Waghorn, and D. T. Denhardt. 1989. Suppression by cathepsin L inhibitors of the invasion of amnion membrane by murine cancer cells. *Cancer Res.* 49:3553-3557.
- Yu, H., and R. M. Schultz. 1990. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. *Cancer Res.* 50:7623-7633.